• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Penumbra wins FDA nod for Ace64 thrombectomy device

Penumbra wins FDA nod for Ace64 thrombectomy device

May 27, 2015 By Fink Densford

Penumbra wins FDA nod on Ace64

Penumbra said today that it has received 510(k) clearance from the FDA for its Ace64 aspiration thrombectomy device, based on data from the Mr. Clean trial and additional randomized controlled stroke trials.

The Ace64 uses a minimally invasive "vacuum" inside arteries to remove blood clots, the Alameda, Calif.-based company said. The device is the largest-lumen aspiration thrombectomy device on the market, according to Penumbra.

The Ace64 is a larger version of its predecessor Ace device, which CEO Adam Elsesser told MassDevice.com can make a serious difference in removing clots.

"What may not seem like a lot makes a significant difference in the ability to directly aspirate clots in the brain," Elsesser told MassDevice.com in an interview. “In treating ischemic stroke, the challenge is always to get the complete clot out as fast as possible, because time matters and the completeness of the revascularization matters. Those are really the 2 factors that devices can control to some degree. We at Penumbra are very excited, because this seems to, in our early experience, improve the completeness of revascularization and lower the time of the procedure, which benefits patients.”

The Ace64 won CE Mark approval in the European Union in December 2014, with an indication for acute ischemic patients with large vessel occlusive disease within eight hours of symptom onset.

"Ace64 is the latest technology improvement in mechanical thrombectomy. I have used Merci and the different stent retrievers as well as the prior Ace aspiration thrombectomy system. With the new Ace64, I am achieving even higher revascularization rates, particularly TICI 3, while reducing procedure times and minimizing overall procedure costs. Ace64 is now my frontline tool for treating patients with acute ischemic stroke," Dr. Rob Lo of the University Medical Center in Utrecht, Holland, said in a press release.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: Penumbra Inc., Stroke

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy